2,4-二甲基苄基溴 | 78831-87-5

• 物质功能分类: 有机原料 - 烃类化合物及其衍生物 - 芳香烃
• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: 2,4-二甲基苄基溴
• 中文别名: 2,4-二甲基溴苄；2,4-二氨基-6-氟嘧啶；2,4-二甲基苄溴
• 英文名称: 2,4-dimethylbenzyl bromide
• 英文别名: 1-(bromomethyl)-2,4-dimethylbenzene
• CAS: 78831-87-5
• 化学式: C₉H₁₁Br
• 分子量: 199.09
• InChiKey: WGLUZJWOTTXZIC-UHFFFAOYSA-N

物化性质

• 熔点：
  15℃
• 沸点：
  235℃
• 密度：
  1.314
• 闪点：
  102℃
• 稳定性/保质期：
  遵照规定使用和储存，则不会发生分解。

计算性质

• 辛醇/水分配系数(LogP)：
  3.2
• 重原子数：
  10
• 可旋转键数：
  1
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.33
• 拓扑面积：
  0
• 氢给体数：
  0
• 氢受体数：
  0

安全信息

• 安全说明：
  S26,S37,S39
• 海关编码：
  2903999090
• 危险品运输编号：
  UN 3265
• 储存条件：
  存储在阴凉干燥的地方即可。

SDS

Name:	2 4-Dimethylbenzyl bromide 98% Material Safety Data Sheet
Synonym:	None Known
CAS:	78831-87-5

Section 1 - Chemical Product MSDS Name:2 4-Dimethylbenzyl bromide 98% Material Safety Data Sheet
Synonym:None Known

---

Section 2 - COMPOSITION, INFORMATION ON INGREDIENTS

CAS#	Chemical Name	content	EINECS#
78831-87-5	2,4-Dimethylbenzyl bromide	98%	unlisted

Hazard Symbols: XI
Risk Phrases: 36/37/38

---

Section 3 - HAZARDS IDENTIFICATION
EMERGENCY OVERVIEW
Irritating to eyes, respiratory system and skin.
Potential Health Effects
Eye:
Causes eye irritation. May cause chemical conjunctivitis.
Skin:
Causes skin irritation. May be harmful if absorbed through the skin.
Ingestion:
May cause irritation of the digestive tract. May be harmful if swallowed.
Inhalation:
Causes respiratory tract irritation. May be harmful if inhaled. Can produce delayed pulmonary edema.
Chronic:
No information found.

---

Section 4 - FIRST AID MEASURES
Eyes: Immediately flush eyes with plenty of water for at least 15 minutes, occasionally lifting the upper and lower eyelids. Get medical aid.
Skin:
Get medical aid. Flush skin with plenty of water for at least 15 minutes while removing contaminated clothing and shoes. Wash clothing before reuse.
Ingestion:
Never give anything by mouth to an unconscious person. Get medical aid. Do NOT induce vomiting. If conscious and alert, rinse mouth and drink 2-4 cupfuls of milk or water. Wash mouth out with water.
Inhalation:
Remove from exposure and move to fresh air immediately. If not breathing, give artificial respiration. If breathing is difficult, give oxygen. Get medical aid. Do NOT use mouth-to-mouth resuscitation.
Notes to Physician:
Treat symptomatically and supportively.

---

Section 5 - FIRE FIGHTING MEASURES
General Information:
As in any fire, wear a self-contained breathing apparatus in pressure-demand, MSHA/NIOSH (approved or equivalent), and full protective gear. During a fire, irritating and highly toxic gases may be generated by thermal decomposition or combustion.
Extinguishing Media:
Use water spray, dry chemical, carbon dioxide, or chemical foam.

---

Section 6 - ACCIDENTAL RELEASE MEASURES
General Information: Use proper personal protective equipment as indicated in Section 8.
Spills/Leaks:
Absorb spill with inert material (e.g. vermiculite, sand or earth), then place in suitable container. Avoid runoff into storm sewers and ditches which lead to waterways. Clean up spills immediately, observing precautions in the Protective Equipment section. Provide ventilation.

---

Section 7 - HANDLING and STORAGE
Handling:
Avoid breathing dust, vapor, mist, or gas. Avoid contact with eyes, skin, and clothing. Keep container tightly closed. Avoid ingestion and inhalation. Use with adequate ventilation. Wash clothing before reuse.
Storage:
Store in a cool, dry place. Store in a tightly closed container.

---

Section 8 - EXPOSURE CONTROLS, PERSONAL PROTECTION
Engineering Controls:
Facilities storing or utilizing this material should be equipped with an eyewash facility and a safety shower. Use adequate ventilation to keep airborne concentrations low.
Exposure Limits CAS# 78831-87-5: Personal Protective Equipment Eyes: Wear appropriate protective eyeglasses or chemical safety goggles as described by OSHA's eye and face protection regulations in 29 CFR 1910.133 or European Standard EN166.
Skin:
Wear appropriate protective gloves to prevent skin exposure.
Clothing:
Wear appropriate protective clothing to prevent skin exposure.
Respirators:
Follow the OSHA respirator regulations found in 29 CFR 1910.134 or European Standard EN 149. Use a NIOSH/MSHA or European Standard EN 149 approved respirator if exposure limits are exceeded or if irritation or other symptoms are experienced.

---

Section 9 - PHYSICAL AND CHEMICAL PROPERTIES

Physical State: Clear liquid
Color: colorless
Odor: Not available.
pH: Not available.
Vapor Pressure: Not available.
Viscosity: Not available.
Boiling Point: Not available.
Freezing/Melting Point: Not available.
Autoignition Temperature: Not available.
Flash Point: Not available.
Explosion Limits, lower: Not available.
Explosion Limits, upper: Not available.
Decomposition Temperature:
Solubility in water:
Specific Gravity/Density:
Molecular Formula: C9H11Br
Molecular Weight: 199.09

---

Section 10 - STABILITY AND REACTIVITY
Chemical Stability:
Stable at room temperature in closed containers under normal storage and handling conditions.
Conditions to Avoid:
None reported.
Incompatibilities with Other Materials:
Strong oxidizing agents.
Hazardous Decomposition Products:
Carbon monoxide, carbon dioxide, hydrogen bromide.
Hazardous Polymerization: Has not been reported

---

Section 11 - TOXICOLOGICAL INFORMATION
RTECS#:
CAS# 78831-87-5 unlisted.
LD50/LC50:
Not available.
Carcinogenicity:
2,4-Dimethylbenzyl bromide - Not listed by ACGIH, IARC, or NTP.

---

Section 12 - ECOLOGICAL INFORMATION

---

Section 13 - DISPOSAL CONSIDERATIONS
Dispose of in a manner consistent with federal, state, and local regulations.

---

Section 14 - TRANSPORT INFORMATION

IATA
Not regulated as a hazardous material.
IMO
Not regulated as a hazardous material.
RID/ADR
Not regulated as a hazardous material.

---

Section 15 - REGULATORY INFORMATION

European/International Regulations
European Labeling in Accordance with EC Directives
Hazard Symbols: XI
Risk Phrases:
R 36/37/38 Irritating to eyes, respiratory system
and skin.
Safety Phrases:
S 26 In case of contact with eyes, rinse immediately
with plenty of water and seek medical advice.
S 37/39 Wear suitable gloves and eye/face
protection.
WGK (Water Danger/Protection)
CAS# 78831-87-5: No information available.
Canada
None of the chemicals in this product are listed on the DSL/NDSL list.
CAS# 78831-87-5 is not listed on Canada's Ingredient Disclosure List.
US FEDERAL
TSCA
CAS# 78831-87-5 is not listed on the TSCA inventory.
It is for research and development use only.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

• 作为反应物：
  描述：

  2,4-二甲基苄基溴 在 三乙胺 、 三氯氧磷 作用下， 以 四氢呋喃 为溶剂， 反应 13.5h， 生成 methyl N-[1-(n-propyl)-2-oxo-1,2,3,4-tetrahydroquinolin-6-yl]-P-(2,4-dimethylbenzyl)phosphonamidate
  参考文献：
  名称：

  SUBSTITUTED OXOTETRAHYDROQUINOLINYLPHOSPHINIC ACID AND PHOSPHINIC ACID AMIDES OR SALTS THEREOF AND USE THEREOF TO INCREASE STRESS TOLERANCE IN PLANTS

  摘要：

  该发明涉及一般式（I）的取代氧代四氢喹啉基磷和磷酰胺以及其盐，其中一般式（I）的基团如描述中所定义，用于增强植物对非生物胁迫的耐受性，并用于促进植物生长和/或增加植物产量。

  公开号：

  US20180199575A1
• 作为产物：
  描述：

  1-(氯甲基)-2,4-二甲苯 在 丙酮 、 sodium bromide 作用下， 生成 2,4-二甲基苄基溴
  参考文献：
  名称：

  428.芳香族侧链反应的机理，特别涉及替代品的极性效应。第四部分。季盐形成的机理

  摘要：

  DOI：

  10.1039/jr9350001840

文献信息

• Copper promoted synthesis of substituted quinolines from benzylic azides and alkynes
  作者：Ching-Zong Luo、Parthasarathy Gandeepan、Yun-Ching Wu、Wei-Chen Chen、Chien-Hong Cheng

  DOI：10.1039/c5ra23065a

  日期：——

  novel copper promoted synthesis of substituted quinolines from various benzylic azides and internal alkynes has been demonstrated. The reaction features a broad substrate scope, high product yields and excellent regioselectivity. In contrast to the known two-step process of acid promoted [4 + 2] cycloaddition reaction and oxidation, the present methodology allows the synthesis of quinolines in a single

  已经证明了一种新颖的铜促进的由各种苄基叠氮化物和内部炔烃合成取代喹啉的方法。该反应具有广泛的底物范围，高产物收率和优异的区域选择性。与酸促进[4 + 2]环加成反应和氧化的已知两步方法相比，本方法可在中性反应条件下一步合成喹啉，并可用于合成具有生物活性的6-氯-2,3-二甲基-4-苯基喹啉（抗寄生虫剂）和3,4-二苯基喹啉-2（1 H）-one（p38αMAP激酶抑制剂）。可能的反应机理涉及将叠氮化苄重排至N-芳基丙氨酸（Schmidt反应），然后与内部炔烃进行分子间[4 + 2]环加成反应。
• Structure-Based Optimization and Discovery of M3258, a Specific Inhibitor of the Immunoproteasome Subunit LMP7 (β5i)
  作者：Markus Klein、Michael Busch、Manja Friese-Hamim、Stefano Crosignani、Thomas Fuchss、Djordje Musil、Felix Rohdich、Michael P. Sanderson、Jeyaprakashnarayanan Seenisamy、Gina Walter-Bausch、Ugo Zanelli、Philip Hewitt、Christina Esdar、Oliver Schadt

  DOI：10.1021/acs.jmedchem.1c00604

  日期：2021.7.22

  acids, which selectively inhibit LMP7 while sparing all other subunits. The exploitation of structural differences between the proteasome subunits culminated in the identification of the highly potent, exquisitely selective, and orally available LMP7 inhibitor 50 (M3258). Based on the strong antitumor activity observed with M3258 in MM models and a favorable preclinical data package, a phase I clinical

  蛋白酶体是泛素依赖性蛋白质降解途径中广泛表达的关键成分，其中包含具有催化活性的亚基（β1、β2 和 β5）。LMP7 (β5i) 是免疫蛋白酶体的一个亚基，是一种主要在造血细胞中表达的诱导型异构体。用于治疗多发性骨髓瘤 (MM) 的临床有效的泛蛋白酶体抑制剂非选择性靶向 LMP7 和组成型蛋白酶体和免疫蛋白酶体的其他亚基，具有相当的效力，这可能会限制这些药物的治疗适用性。在这里，我们描述了新型酰氨基硼酸的发现和基于结构的命中优化，它选择性地抑制 LMP7，同时保留所有其他亚基。对蛋白酶体亚基之间结构差异的开发最终确定了高效能，50 (M3258)。基于 M3258 在 MM 模型中观察到的强大抗肿瘤活性和有利的临床前数据包，在复发/难治性 MM 患者中启动了 I 期临床试验。
• [EN] FUSED HETEROCYCLIC COMPOUNDS AS S1P MODULATORS<br/>[FR] COMPOSÉS HÉTÉROCYCLIQUES CONDENSÉS À TITRE DE MODULATEURS DE S1P
  申请人：ABBVIE INC

  公开号：WO2017036978A1

  公开（公告）日：2017-03-09

  The invention relates to heterocyclic compounds as S1P modulators, pharmaceutical compositions comprising such compounds, and uses thereof in the treatment, alleviation or prevention of diseases or disorders mediated by an S1P receptor.

  这项发明涉及杂环化合物作为S1P调节剂，包括这种化合物的药物组合物，以及在治疗、缓解或预防由S1P受体介导的疾病或紊乱中的用途。
• C -2 ( E )-4-(Styryl)aniline substituted diphenylpyrimidine derivatives (Sty-DPPYs) as specific kinase inhibitors targeting clinical resistance related EGFR T790M mutant
  作者：Anran Song、Jianbin Zhang、Yang Ge、Changyuan Wang、Qiang Meng、Zeyao Tang、Jinyong Peng、Kexin Liu、Yanxia Li、Xiaodong Ma

  DOI：10.1016/j.bmc.2017.03.032

  日期：2017.5

  With the aim to overcome the drug resistance induced by the EGFR T790M mutation (EGFRT790M), herein, a family of diphenylpyrimidine derivatives (Sty-DPPYs) bearing a C-2 (E)-4-(styryl)aniline functionality were designed and synthesized as potential EGFRT790M inhibitors. Among them, the compound 10e displayed strong potency against the EGFRT790M enzyme, with the IC50 of 11.0nM. Compound 10e also showed

  为了克服由EGFR T790M突变（EGFRT790M）诱导的耐药性，本文设计并合成了具有C-2（E）-4-（苯乙烯基）苯胺官能度的二苯基嘧啶衍生物（Sty-DPPYs）家族。作为潜在的EGFRT790M抑制剂。其中，化合物10e对EGFRT790M酶具有很强的效力，IC50为11.0nM。化合物10e还显示出比罗西替尼（SI = 21.4）更高的SI值（SI = 49.0），表明其副作用较小。另外，化合物10e可以在2.91μM的浓度范围内有效抑制具有EGFRT790M突变的H1975细胞的增殖。值得注意的是，化合物10e对正常的HBE细胞毒性低（IC50 =22.48μM）。
• Ruthenium-Catalyzed Site-Selective Intramolecular Silylation of Primary C–H Bonds for Synthesis of Sila-Heterocycles
  作者：Huaquan Fang、Wenjun Hou、Guixia Liu、Zheng Huang

  DOI：10.1021/jacs.7b06798

  日期：2017.8.23

  medicinal chemistry. Moreover, organosilanes are valuable synthetic intermediates for fine chemicals and materials. Transition metal-catalyzed C-H silylation has become an important strategy for C-Si bond formations. However, despite the great advances in aromatic C(sp2)-H bond silylations, catalytic methods for aliphatic C(sp3)-H bond silylations are relatively rare. Here we report a pincer ruthenium

  将硅元素掺入具有生物活性的有机分子在药物化学中受到越来越多的关注。此外，有机硅烷是精细化学品和材料的宝贵合成中间体。过渡金属催化的 CH 硅烷化已成为 C-Si 键形成的重要策略。然而，尽管在芳族 C(sp2)-H 键硅烷化方面取得了很大进展，但脂肪族 C(sp3)-H 键硅烷化的催化方法相对较少。在这里，我们报告了一种钳状钌催化剂，用于与杂原子（O、N、Si、Ge）相邻的各种初级 C(sp3)-H 键的分子内硅烷化，包括 CH 键 α 到 O、N 和 Ge 的第一次分子内硅烷化。该方法为新型含硅五元 [1,3]-硅杂环提供了一种通用的、综合有效的方法，包括氧杂环戊烷、氮杂硅氧烷、二硅杂环和锗硅烷。阐明了五类 C(sp3)-H 键对 Ru 催化的甲硅烷基化反应的趋势。机理研究表明，决定速率的步骤是 CH 键断裂，其中涉及作为关键中间体的钌甲硅烷基复合物，而 η2-甲硅烷基氢化钌物种被确定为非循环中间体。